Table 2.
5-11 years (n = 1,842,159) | 12-17 years (n = 3,355,766) | |||||||
---|---|---|---|---|---|---|---|---|
Dose 1 | Dose 2 | Dose 3 | Positive SARS-CoV-2 test | Dose 1 | Dose 2 | Dose 3 | Positive SARS-CoV-2 test | |
Total N | 581,545 | 303,118 | 870 | 1,508,661 | 2,882,229 | 2,254,214 | 454,868 | 1,602,710 |
Type of vaccine | ||||||||
BNT162b2 | 581,356 ( > 99.9) | 303,045 ( > 99.9) | 870 (100) | - | 2,870,403 (99.6) | 2,240,546 (99.4) | 399,845 (87.9) | - |
ChAdOX1 | 97 ( < 0.1) | 13 ( < 0.1) | 0 (0) | - | 10,245 (0.4) | 9190 (0.4) | 46 ( < 0.1) | - |
mRNA-1273 | 92 ( < 0.1) | 60 ( < 0.1) | 0 (0) | - | 1581 ( < 0.1) | 4478 (0.2) | 54,977 (12.1) | - |
Vaccine status | ||||||||
No vaccine | - | - | - | 83.6 (1,260,614) | - | - | - | 29.5 (473,537) |
Dose 1 | 100 (581,545) | 100 (303,118) | 100 (870) | 16.4 (248047) | 100 (2,882,229) | 100 (2,254,214) | 100 (454,868) | 70.5 (1,129,173) |
Dose 2 | 52.1 (303,118) | 100 (303,118) | 100 (870) | 8.9 (133998) | 78.2 (2,254,214) | 100 (2,254,214) | 100 (454,868) | 54.4 (872,128) |
Dose 3 | 0.1 (870) | 0.3 (870) | 100 (870) | < 0.1 (431) | 15.8 (454,868) | 20.2 (454,868) | 100 (454,868) | 9.9 (159,350) |
Positive SARS-CoV-2 test during study period | ||||||||
None | 57.3 (333,498) | 55.8 (169,120) | 50.5 (439) | - | 60.8 (1,753,056) | 61.3 (1,382,086) | 65.0 (295,518) | - |
Prior to first vaccine dose | 41.7 (242,382) | 43.2 (131,034) | 40.8 (355) | 99.6 (1,502,996) | 20.8 (598,477) | 20.1 (454,034) | 12.0 (54,765) | 66.9 (1,072,014) |
After first vaccine dose | 1.0 (5665) | 1.0 (2964) | 8.7 (76) | 0.4 (5665) | 18.4 (530,696) | 18.5 (418,094) | 23.0 (104,585) | 33.1 (530,696) |
Cells with < 5 are suppressed. Data are presented as column % (counts).